Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CPRXNASDAQ:CRNXNASDAQ:HCMNASDAQ:PHAT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$22.81-1.8%$23.91$14.75▼$26.58$2.83B0.721.14 million shs1.47 million shsCRNXCrinetics Pharmaceuticals$30.50-1.1%$31.35$24.10▼$62.53$2.89B0.28845,032 shs480,466 shsHCMHUTCHMED$15.43-1.8%$14.56$11.51▼$21.50$2.74B0.5299,966 shs39,187 shsPHATPhathom Pharmaceuticals$10.90+3.8%$4.98$2.21▼$19.71$733.05M0.081.51 million shs2.61 million shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals-1.90%-11.74%-4.72%+2.74%+54.80%CRNXCrinetics Pharmaceuticals-1.12%-6.74%-1.25%-11.02%-31.00%HCMHUTCHMED-6.43%-6.71%+17.33%-2.90%-12.14%PHATPhathom Pharmaceuticals-1.32%+17.06%+156.72%+72.70%-10.26%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCPRXCatalyst Pharmaceuticals4.8877 of 5 stars3.62.00.03.93.83.33.1CRNXCrinetics Pharmaceuticals3.5287 of 5 stars3.50.00.03.72.72.50.0HCMHUTCHMED1.338 of 5 stars2.02.00.00.02.00.01.9PHATPhathom Pharmaceuticals3.849 of 5 stars4.52.00.00.01.95.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPRXCatalyst Pharmaceuticals 3.25Buy$32.8343.94% UpsideCRNXCrinetics Pharmaceuticals 2.91Moderate Buy$74.56144.44% UpsideHCMHUTCHMED 2.00Hold$19.0023.14% UpsidePHATPhathom Pharmaceuticals 3.00Buy$17.5060.55% UpsideCurrent Analyst Ratings BreakdownLatest PHAT, HCM, CRNX, and CPRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025PHATPhathom PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $17.006/9/2025PHATPhathom PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.006/6/2025PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.006/5/2025CPRXCatalyst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025HCMHUTCHMEDHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold5/2/2025PHATPhathom PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $5.005/2/2025PHATPhathom PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $12.005/2/2025PHATPhathom PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $20.004/21/2025PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.004/17/2025PHATPhathom PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$12.00 ➝ $10.004/9/2025PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPRXCatalyst Pharmaceuticals$491.73M5.66$2.40 per share9.49$6.10 per share3.74CRNXCrinetics Pharmaceuticals$1.04M2,745.88N/AN/A$14.29 per share2.13HCMHUTCHMED$630.20M4.27$0.28 per share54.69$4.43 per share3.48PHATPhathom Pharmaceuticals$55.25M13.77N/AN/A($3.71) per share-2.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPRXCatalyst Pharmaceuticals$163.89M$1.5714.5310.710.9536.91%42.45%36.59%8/6/2025 (Estimated)CRNXCrinetics Pharmaceuticals-$298.41M-$3.82N/AN/AN/AN/A-30.95%-28.12%8/6/2025 (Estimated)HCMHUTCHMED$37.73MN/A0.0010.57N/AN/AN/AN/A6/18/2025 (Estimated)PHATPhathom Pharmaceuticals-$334.33M-$5.24N/AN/AN/A-422.42%N/A-90.11%8/6/2025 (Estimated)Latest PHAT, HCM, CRNX, and CPRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CRNXCrinetics Pharmaceuticals-$0.99-$1.04-$0.05-$1.04$0.10 million$0.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/ACRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPRXCatalyst PharmaceuticalsN/A6.145.96CRNXCrinetics PharmaceuticalsN/A22.5322.53HCMHUTCHMED0.082.832.70PHATPhathom PharmaceuticalsN/A3.583.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPRXCatalyst Pharmaceuticals79.22%CRNXCrinetics Pharmaceuticals98.51%HCMHUTCHMED8.82%PHATPhathom Pharmaceuticals99.01%Insider OwnershipCompanyInsider OwnershipCPRXCatalyst Pharmaceuticals10.40%CRNXCrinetics Pharmaceuticals4.60%HCMHUTCHMED3.60%PHATPhathom Pharmaceuticals23.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPRXCatalyst Pharmaceuticals80121.97 million109.29 millionOptionableCRNXCrinetics Pharmaceuticals21093.63 million89.32 millionOptionableHCMHUTCHMED1,811174.32 million168.05 millionNot OptionablePHATPhathom Pharmaceuticals11069.81 million53.76 millionOptionablePHAT, HCM, CRNX, and CPRX HeadlinesRecent News About These CompaniesPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Rating of "Buy" by BrokeragesJune 18 at 5:46 AM | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 4.6% - Should You Sell?June 16 at 2:16 PM | marketbeat.comPhathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032June 16 at 8:00 AM | globenewswire.comPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up - Should You Buy?June 12, 2025 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading 6.4% Higher - Should You Buy?June 11, 2025 | marketbeat.comTiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: BuyJune 10, 2025 | seekingalpha.comCraig Hallum Raises Phathom Pharmaceuticals (NASDAQ:PHAT) Price Target to $17.00June 10, 2025 | americanbankingnews.comPhathom Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:PHAT)June 10, 2025 | americanbankingnews.comPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 9.7% - Here's What HappenedJune 9, 2025 | marketbeat.comPhathom: Share Price Surge On Patent News May Not Stop The Rot For LongJune 9, 2025 | seekingalpha.comTraders Purchase High Volume of Call Options on Phathom Pharmaceuticals (NASDAQ:PHAT)June 9, 2025 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Given New $17.00 Price Target at Craig HallumJune 9, 2025 | marketbeat.comWall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to TradeJune 9, 2025 | zacks.comPhathom Pharmaceuticals (NASDAQ:PHAT) Given "Buy" Rating at HC WainwrightJune 9, 2025 | marketbeat.comPhathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets through May 3, 2032June 9, 2025 | finanznachrichten.deStifel analysts affirm Buy rating for Phathom Pharmaceuticals stockJune 7, 2025 | investing.comWellington Management Group LLP Sells 37,388 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)June 7, 2025 | marketbeat.comPhathom Pharmaceuticals shares soar on FDA exclusivity grantJune 6, 2025 | uk.finance.yahoo.comPhathom Pharmaceuticals price target raised to $29 from $23 at Cantor FitzgeraldJune 6, 2025 | msn.comPhathom surges 125% after FDA grants petition on Voquezna exclusivityJune 6, 2025 | msn.comPhathom Pharmaceuticals' (PHAT) Buy Rating Reiterated at Needham & Company LLCJune 6, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePHAT, HCM, CRNX, and CPRX Company DescriptionsCatalyst Pharmaceuticals NASDAQ:CPRX$22.81 -0.41 (-1.77%) Closing price 04:00 PM EasternExtended Trading$23.11 +0.30 (+1.32%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Crinetics Pharmaceuticals NASDAQ:CRNX$30.50 -0.35 (-1.13%) Closing price 04:00 PM EasternExtended Trading$30.51 +0.01 (+0.03%) As of 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.HUTCHMED NASDAQ:HCM$15.43 -0.28 (-1.78%) Closing price 04:00 PM EasternExtended Trading$15.55 +0.12 (+0.77%) As of 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Phathom Pharmaceuticals NASDAQ:PHAT$10.90 +0.40 (+3.81%) Closing price 04:00 PM EasternExtended Trading$10.80 -0.10 (-0.92%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
